Decentralised clinical trials (DCTs) have existed for years in different shapes and forms. Urged by the COVID-19 pandemic, restrictions to in-person patient visits and other challenges with access accelerated
the implementation of new tools and technologies to keep trials moving forward. Rik Van Mol at Veeva Systems reveals that the pandemic also unveiled many of the challenges of traditional clinical trial models, including the fragmented use of digital, stand-alone applications.